News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phenomix Corporation Initiates Phase 1a Clinical Trial of Hepatitis C Protease Inhibitor PHX1766


10/28/2008 8:41:17 AM

SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company’s internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The study is being conducted at clinical sites in the Netherlands and will enroll approximately 24 healthy subjects and six HCV infected patients.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES